Vega Therapeutics Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2B
Vega Therapeutics General Information
Description
Operator of a clinical-stage biotechnology company intended to focus on addressing overlooked needs in rare blood disorders. The company specialises in developing novel therapies for rare blood disorders with overlooked patient needs, with a mechanism of action targeting Protein S, which augments and restores thrombin generation during both initiation and propagation of coagulation, enabling patients with von Willebrand disease to manage bleeding through subcutaneous injections rather than frequent intravenous infusions.
Contact Information
Website
www.vega-therapeutics.comCorporate Office
- 201 Haskins Way
- 5th Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 201 Haskins Way
- 5th Floor
- South San Francisco, CA 94080
- United States
Vega Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 06-Jul-2026 | $2B | Completed | Clinical Trials - General | ||
| 2. Early Stage VC | Completed | Clinical Trials - General | ||||
| 1. Spin-Off | 01-Jan-2018 | Completed | Clinical Trials - General |
Vega Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vega Therapeutics Patents
Vega Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025240928-A1 | Treatment of von willebrand disease | Pending | 16-May-2024 | ||
| WO-2024124136-A1 | Von willebrand disease animal models | Inactive | 09-Dec-2022 | ||
| AU-2021268943-A1 | Protein s antibodies, methods of making and uses thereof | Pending | 05-May-2020 | ||
| CA-3177329-A1 | Protein s antibodies, methods of making and uses thereof | Pending | 05-May-2020 | ||
| EP-4146705-A1 | Protein s antibodies, methods of making and uses thereof | Pending | 05-May-2020 | C07K16/36 |
Vega Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| NYBC Ventures | Corporate Venture Capital | Minority | ||
| New Leaf Venture | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority |
Vega Therapeutics FAQs
-
When was Vega Therapeutics founded?
Vega Therapeutics was founded in 2018.
-
Where is Vega Therapeutics headquartered?
Vega Therapeutics is headquartered in South San Francisco, CA.
-
What industry is Vega Therapeutics in?
Vega Therapeutics’s primary industry is Drug Discovery.
-
Is Vega Therapeutics a private or public company?
Vega Therapeutics is a Private company.
-
What is the current valuation of Vega Therapeutics?
The current valuation of Vega Therapeutics is .
-
What is Vega Therapeutics’s current revenue?
The current revenue for Vega Therapeutics is .
-
How much funding has Vega Therapeutics raised over time?
Vega Therapeutics has raised $40M.
-
Who are Vega Therapeutics’s investors?
Cormorant Asset Management, Cowen Healthcare Investments, NYBC Ventures, New Leaf Venture, and OrbiMed are 5 of 9 investors who have invested in Vega Therapeutics.
-
When was Vega Therapeutics acquired?
Vega Therapeutics was acquired on 06-Jul-2026.
-
Who acquired Vega Therapeutics?
Vega Therapeutics was acquired by Incyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
